固酶抑制剂的生物学影响和治疗潜力:一篇综述
Mansour Alnazari1, Abdulaziz Bakhsh1, Sulaiman Abdullah1
1Department of General and Specialized Surgery, College of Medicine, Taibah University, Madinah, Saudi Arabia.
Medicine
|March 6, 2026
概括
固醇酶 (PDE) 抑制剂调节循环核酸路径,用于各种疾病. 本综述详细介绍了它们的治疗用途,挑战以及改善选择性和安全性的未来方向.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 固酶 (PDE) 抑制剂调节周期性腺单酸盐 (cAMP) 和周期性关单酸盐 (cGMP) 途径.
- 存在多个PDE家族,具有不同的生物学作用和治疗潜力.
- PDEs被分为双基质 (PDE1,PDE2,PDE3,PDE10,PDE11) 或非双基质 (PDE4,PDE5,PDE6,PDE7,PDE8,PDE9) 的类型.
研究的目的:
- 总结PDE抑制剂在各种疾病领域的治疗应用.
- 评估支持在不同条件下使用PDE抑制剂的证据.
- 突出PDE抑制剂开发中的挑战和未来研究重点.
主要方法:
- 发表的研究和临床试验数据的叙述性综述.
- 专注于PDE抑制剂的药理特性,治疗相关性和安全性.
- 搜索了包括PubMed,ClinicalTrials.gov和监管报告在内的数据库.
主要成果:
- 双基质PDEs在阿尔茨海默病 (PDE1),焦虑/记忆 (PDE2) 和心力衰竭 (PDE3) 中表现出潜力,并指出PDE3抑制剂的风险.
- 非双基质的PDE如PDE4和PDE5已被确立用于喘,COPD,牛皮,勃起功能障碍和肺高血压.
- 结构-活性关系的进步已经产生了更有选择性的抑制剂,但恶心 (PDE4) 和心血管风险 (PDE3) 等不良影响仍然存在.
结论:
- PDE 抑制剂是一种具有广泛临床应用的动态治疗类.
- 进一步发展需要策略来增强选择性并最大限度地减少不利影响.
- 未来的研究应该优先考虑精准医学方法,以获得最佳的治疗结果.
更多相关视频
10:31A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
Published on: September 26, 2025
581
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
9.6K
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
671
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
671
02:54Protein Kinases and Phosphatases
15.4K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.4K
01:01Phosphodiester Linkages
112.9K
Overview
Phosphodiester bond forms when a phosphoric acid molecule (H3PO4) links with two hydroxyl groups (–OH) of two other molecules, forming two ester bonds. Two water molecules are released in this process. The phosphodiester bond is commonly found in nucleic acids (DNA and RNA) and plays a critical role in their structure and function.
Phosphodiester Bonds Link Nucleotides Together
DNA and RNA are polynucleotides or long chains of nucleotides that are linked together. A nucleotide is...
Phosphodiester bond forms when a phosphoric acid molecule (H3PO4) links with two hydroxyl groups (–OH) of two other molecules, forming two ester bonds. Two water molecules are released in this process. The phosphodiester bond is commonly found in nucleic acids (DNA and RNA) and plays a critical role in their structure and function.
Phosphodiester Bonds Link Nucleotides Together
DNA and RNA are polynucleotides or long chains of nucleotides that are linked together. A nucleotide is...
112.9K
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.6K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.6K
01:42Phosphoinositides and PIPs
10.4K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
10.4K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
564
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
564